Literature DB >> 3109914

Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.

R J Hamer, J A Koedam, N H Beeser-Visser, R M Bertina, J A Van Mourik, J J Sixma.   

Abstract

The formation of a complex between factor VIII (FVIII) and von Willebrand factor (vWF) was studied using purified radiolabeled human FVIII and purified human vWF. A binding assay was developed in which vWF was coated on microtiter wells. FVIII was shown to bind specifically and reversibly to the immobilized vWF. At a coating of 70 pg vWF/well, binding was half-maximal at a FVIII concentration of 70 +/- 10 pM. In order to ascertain which part of FVIII interacted with vWF, eight monoclonal antibodies, directed against FVIII, were tested for their ability to inhibit FVIII-vWF interaction. One of the eight antibodies, CLB-CAg:58, inhibited binding completely. This antibody was demonstrated to react with the Mr-80,000 light chain of FVIII. Direct evidence for the involvement of this chain in vWF binding was obtained by studying the binding of isolated, radiolabeled FVIII heavy and light chains. In a typical experiment 23-30% of the radioactivity bound when the FVIII light chain was added and less than 1% when the FVIII heavy chain was added.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109914     DOI: 10.1111/j.1432-1033.1987.tb13480.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  23 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.

Authors:  Marco Campos; Ashley Buchanan; Fuli Yu; Maja Barbalic; Yang Xiao; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; Eric Boerwinkle; Jing-fei Dong
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

4.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

5.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  Immunohistochemical localization of vascular endothelial cell factor VIII/von Willebrand factor antigen in human normal and disordered gastric tissues.

Authors:  S L Shen; Y H Xu; Z B Wu
Journal:  J Tongji Med Univ       Date:  1989

7.  Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.

Authors:  Q Shi; E L Kuether; J A Schroeder; C L Perry; S A Fahs; J Cox Gill; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

8.  The influence of von Willebrand factor on factor VIII activity measurements.

Authors:  S Butenas; B Parhami-Seren; K G Mann
Journal:  J Thromb Haemost       Date:  2008-10-29       Impact factor: 5.824

Review 9.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

10.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.